EDAP Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results

Planet edap Inc.
Mar 12,2008

EDAP Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results

EDAP Announces Webcast and Conference Call of Fourth Quarter and Full Year 2007 Results

LYON, France, March 12, 2008 (PRIME NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in high-intensity focused ultrasound (HIFU) for the treatment of prostate cancer, announced today details relating to its fourth quarter and full year 2007 earnings announcement, which will take place on Wednesday, March 26, 2008, before the open of the market.

EDAP will hold a conference call on Wednesday, March 26, 2008 at 8:30 a.m. ET to discuss the results. The dial-in numbers are 1-800-374-0113 for domestic callers and 1-706-758-9607 for international. The conference ID number for both is 39006506. A live Webcast of the conference call will be available online from the investor relations page of the Company's corporate Website at www.edap-tms.com.

After the live Webcast, the call will remain available on EDAP's Website, www.edap-tms.com, through June 26, 2008. In addition, a telephonic replay of the call will be available until April 3, 2008. The replay dial-in numbers are 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. Please use event ID number 39006506.

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the company, please visit http://www.edap-tms.com and http://www.hifu-planet.com or http://www.urotoday.com/HIFU.

CONTACT:  EDAP TMS SA
          Investor Relations / Legal Affairs
          Blandine Confort
          +33 4 72 15 31 72
          bconfort@edap-tms.com 

          The Ruth Group
          Investors:
          Stephanie Carrington 
          646-536-7017
          scarrington@theruthgroup.com

          R.J. Pellegrino
          646-536-7009
          rpellegrino@theruthgroup.com